Cargando…

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Detalles Bibliográficos
Autores principales:	Abu-Raddad, Laith J, Chemaitelly, Hiam, Yassine, Hadi M, Benslimane, Fatiha M, Al Khatib, Hebah A, Tang, Patrick, Malek, Joel A, Coyle, Peter, Ayoub, Houssein H, Al Kanaani, Zaina, Al Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F, Nasrallah, Gheyath K, Al Kuwari, Mohamed Ghaith, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H, Al Khal, Abdullatif, Butt, Adeel A, Bertollini, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194836/ https://www.ncbi.nlm.nih.gov/pubmed/34050372 http://dx.doi.org/10.1093/jtm/taab083

Ejemplares similares

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
por: Abu-Raddad, Laith J, et al.
Publicado: (2021)

Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience
por: Bsat, Raghid, et al.
Publicado: (2022)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2021)

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

History of primary-series and booster vaccination and protection against Omicron reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
por: Altarawneh, Heba N., et al.
Publicado: (2023)

Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
por: Qassim, Suelen H., et al.
Publicado: (2023)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19
por: Ayoub, Houssein H, et al.
Publicado: (2021)

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar
por: Seedat, Shaheen, et al.
Publicado: (2021)

SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
por: Mahmoud, Mai A., et al.
Publicado: (2023)

Duration of immune protection of SARS-CoV-2 natural infection against reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

1966. Protection afforded by prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections.
por: Altarawneh, Heba N, et al.
Publicado: (2022)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Covid-19 Vaccine Protection among Children and Adolescents in Qatar
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
por: Nasrallah, Gheyath K., et al.
Publicado: (2021)

Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections
por: Qassim, Suelen H, et al.
Publicado: (2022)

Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting
por: Abu-Raddad, Laith J, et al.
Publicado: (2020)

Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
por: Qassim, Suelen H., et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
por: Coyle, Peter V., et al.
Publicado: (2021)

Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2
por: Coyle, Peter V., et al.
Publicado: (2022)

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
por: AlNuaimi, Asma A, et al.
Publicado: (2023)

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar
por: Tayar, Elias, et al.
Publicado: (2023)

Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar
por: Jeremijenko, Andrew, et al.
Publicado: (2021)

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020
por: Al Kuwari, Hanan M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gi6ah2l5gatqm3ld5ia0v40ebp